Hepatitis Clinical Trials

• Age from 18 to 65 years old;

• Clinical diagnosis of chronic hepatitis b virus infection (positive hepatitis b surface antigen or positive hepatitis b virus DNA \> 0.5 year);

• Clinical diagnosis of hepatocellular carcinoma and receive immune checkpoint inhibitors treatment. The last treatment of immune checkpoint inhibitors is less than three months from inclusion;

• The level of hepatitis b virus DNA \< 2000 IU/mL；

• Serum aspartate aminotransferase/alanine aminotransferase \> 20 times upper limit of normal；serum total bilirubin\>10 times upper limit of normal；

• Prothrombin time international ratio \> 1.5;

• Platelets \> 50\*10 E9/L;

• Without intrahepatic bile duct dilation due to tumor progression.